Aptose Biosciences Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand how Aptose Biosciences performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Aptose develops precision cancer drugs, specifically targeting blood cancers like leukemia and high-risk bone marrow disorders. Because they have no FDA-approved products yet, they earn no money from sales. Instead, they spend heavily on research—about $38.4 million in 2024—and rely on selling shares to investors to keep the operations running.

2. The Big News: A Potential Buyout

The most important update is that Aptose plans to sell the company. On November 18, 2025, they agreed to be acquired by Hanmi Pharmaceutical for about C$115 million.

If the deal closes, you will receive C$2.41 in cash for each share you own. The company expects the deal to finish in the first half of 2026, pending shareholder and regulatory approval. This represents a significant shift from their previous strategy of raising capital through share offerings to fund their own research.

3. Clinical Progress

Aptose has focused on their lead drug, tuspetinib (TUS). In the APTIVATE clinical trial, patients with hard-to-treat leukemia entered remission, even after other treatments failed. The drug showed success in patients with difficult genetic mutations. They also began testing TUS alongside other standard treatments, a key step toward establishing it as a go-to therapy.

4. Financial Health and Risks

Aptose is currently spending more than it earns, reporting a $41.2 million loss for 2024. As of their last report, they held about $12.5 million in cash.

The risks have shifted:

• The Buyout Risk: The deal is not guaranteed. If it fails—perhaps due to a shareholder vote or regulatory hurdles—the company will face a difficult financial position. They would likely need to sell more shares to stay afloat, which would reduce your ownership percentage and value.
• Dilution: Before the buyout, Aptose frequently sold more shares to raise cash. If the deal collapses, they will likely return to this practice, which historically has reduced value for existing shareholders.
• Clinical Success: The buyout price assumes the drug data is solid. If regulators raise concerns about the drug’s safety or the durability of the remissions, the company’s value could drop significantly, regardless of the pending deal.

5. The Bottom Line

The investment story has changed from "Will their drug work?" to "Will this deal close?" The stock price now mostly reflects the C$2.41 buyout offer. If you believe the deal will close, you are effectively betting on that cash payout. If you are concerned the deal might collapse, the risks are high, as the company’s financial future remains dependent on external funding without the acquisition.

Decision Checklist:

• If you are a current shareholder: Monitor the proxy statement for the shareholder vote and any updates regarding regulatory approval.
• If you are considering buying: Understand that you are essentially trading on the probability of the merger closing. The stock will likely trade near the C$2.41 offer price until the deal is either finalized or terminated.